Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study finds.

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Multiple sclerosis (MS) is a condition that disrupts the information pathways that connect your brain and your body. From time to time, the symptoms of MS can unexpectedly worsen. When symptoms ...

CareDx (NASDAQ:CDNA) used an investor webcast to outline its “Transplant Plus” expansion into cell therapy and to highlight ...

Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections ...

In 2013, Jowita Bydlowska released her groundbreaking memoir Drunk Mom, an unflinching account of how new motherhood sparked her full-blown return to alcoholism. The book was a vital addition to ...

Understand all about childhood cancer relapse rates in India. Know the risk factors, warning signs, treatment options and survival outcomes to help parents make informed medical decisions.